| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300871 | 回盛生物 | 23.52 | -5.24% | 27.00万 | 6.43 乙 | | 688098 | 申联生物 | 8.51 | -3.62% | 29.97万 | 2.57亿 | | 002868 | *ST绿康 | 26.30 | -1.50% | 1.45万 | 3804.68万 | | 603718 | 海利生物 | 7.58 | -1.17% | 9.42万 | 7168.65万 | | 688526 | 科前生物 | 16.96 | -0.88% | 3.74万 | 6337.08万 | | 839729 | 永顺生物 | 10.02 | -0.79% | 4.50万 | 4535.21万 | | 600195 | 中牧股份 | 7.61 | -0.78% | 9.50万 | 7231.88万 | | 838275 | 驱动力 | 10.02 | -0.60% | 1.65万 | 1640.86万 | | 6035 ...

Market Overview - The animal health sector increased by 1.46% on August 5, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3617.6, up 0.96%, while the Shenzhen Component Index closed at 11106.96, up 0.59% [1] Stock Performance - Shenlian Biological (688098) closed at 8.83, up 10.79% with a trading volume of 410,700 shares and a turnover of 348 million yuan [1] - Xianfeng Holdings (002141) closed at 3.81, up 4.10% with a trading volume of 732,700 shares and a turnover of 280 million yuan [1] - Jinhai Biological (002688) closed at 7.60, up 3.54% with a trading volume of 645,200 shares and a turnover of 487 million yuan [1] - Huisheng Biological (300871) closed at 24.82, up 1.85% with a trading volume of 260,400 shares and a turnover of 636 million yuan [1] Capital Flow - The animal health sector saw a net inflow of 138 million yuan from institutional investors, while retail investors experienced a net outflow of 127 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors showing confidence while retail investors are withdrawing [2] Individual Stock Capital Flow - Jinhai Biological had a net inflow of 40.62 million yuan from institutional investors, while retail investors had a net outflow of 29.52 million yuan [3] - Huisheng Biological saw a net inflow of 36.65 million yuan from institutional investors, but a significant outflow of 74.58 million yuan from retail investors [3] - Shenlian Biological experienced a net inflow of 18.09 million yuan from institutional investors, with retail investors withdrawing 20.78 million yuan [3]

融券方面，当日无融券交易。 融资融券余额1.12亿元，较昨日上涨2.5%。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-08-04 | 1.12亿 | 273.39万 | 2.50% | | 2025-08-01 | 1.09亿 | 108.65万 | 1.00% | | 2025-07-31 | 1.08亿 | 734.73万 | 7.28% | | 2025-07-30 | 1.01亿 | 560.02万 | 5.88% | | 2025-07-29 | 9528.47万 | 80.83万 | 0.86% | 证券之星消息，8月4日，申联生物（688098）融资买入3009.67万元，融资偿还2736.28万元，融资净买 入273.39万元，融资余额1.12亿元，近3个交易日已连续净买入累计1116.77万元。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-04 | 273.39万 | 1.12亿 | 3.42% ...

Market Overview - The animal health sector increased by 0.65% on August 4, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Stock Performance - BioShares (600201) closed at 8.75, rising by 2.70% with a trading volume of 327,100 shares and a turnover of 280 million yuan [1] - Jinhe Biology (002688) closed at 7.34, up 2.51%, with a trading volume of 666,900 shares and a turnover of 485 million yuan [1] - Ruipu Biology (300119) closed at 21.58, increasing by 1.27%, with a trading volume of 72,800 shares and a turnover of 155 million yuan [1] - KQ Biology (688526) closed at 17.00, up 1.01%, with a trading volume of 29,600 shares and a turnover of 49.88 million yuan [1] - Other notable stocks include Dayu Biology (871970) at 10.40 (+0.97%) and Zeng Caike (603566) at 15.00 (+0.87%) [1] Capital Flow - The animal health sector saw a net inflow of 68.12 million yuan from institutional investors, while retail investors experienced a net outflow of 58.45 million yuan [2] - The main capital inflow and outflow for specific stocks include: - Jinhe Biology: 70.12 million yuan inflow from main investors, 33.36 million yuan outflow from retail investors [3] - BioShares: 15.45 million yuan inflow from main investors, 8.61 million yuan outflow from retail investors [3] - Shilian Biology (688098): 3.79 million yuan inflow from main investors, 27.89 million yuan outflow from retail investors [3]

Group 1 - Pharmaceutical stocks continued to decline in early trading, with companies like Kexing Pharmaceutical and Bioventure dropping over 11% [1] - Other companies such as Aoxiang Pharmaceutical, Shenlian Biological, Anke Biotechnology, Zhongsheng Pharmaceutical, and Haichuang Pharmaceutical experienced declines of over 6% [1]

Core Viewpoint - Shanyuan Biological has shown significant financing activity with a net buy of 14.68 million yuan last week, indicating investor interest and potential growth in the biopharmaceutical sector [1] Financing Activity - Shanyuan Biological recorded a total financing buy of 57.79 million yuan and repayment of 43.11 million yuan last week [1] - The company ranked 491st in terms of net financing buy across the market [1] Capital Flow - Over the past 5 days, the main capital inflow into Shanyuan Biological was 71.45 million yuan, with a price increase of 13.32% [1] - In the last 10 days, the capital inflow was 71.48 million yuan, reflecting a price increase of 10.0% [1] Company Profile - Shanyuan Biological Pharmaceutical (Shanghai) Co., Ltd. was established in 2001 and is located in Shanghai, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 410.644 million yuan and a paid-in capital of 316.897548 million yuan [1] - The legal representative of the company is Nie Dongsheng [1] Investment and Intellectual Property - Shanyuan Biological has invested in 7 external companies and participated in 1,602 bidding projects [1] - The company holds 31 trademark registrations and 143 patents, along with 54 administrative licenses [1]

Group 1 - The company, Shenlian Biopharmaceutical, announced the successful integration of self-assembling nanoparticle technology with circular mRNA technology to develop the world's first circular mRNA vaccine for swine fever, achieving significant progress [1] - The research results have been published in the internationally recognized immunology journal, "Frontiers in Immunology," indicating the credibility and scientific validation of the findings [1] - The new vaccine is expected to innovate in both antibody persistence and production cost, providing a novel solution for swine fever purification [1] Group 2 - The traditional swine fever E2 subunit vaccine has been crucial in swine fever purification due to its excellent biosafety characteristics and the ability to distinguish between infected and immune animals, but high production costs have limited its widespread application [1] - The company has developed a new generation of swine fever E2 glycoprotein vaccine using a self-built mRNA-LNP technology platform, which combines high immunogenicity with cost-effectiveness [1] - The research team compared different cationic lipid formulations in cmRNA-LNP preparations, finding that the AX4-LNP formulation induced superior cellular and humoral immunity compared to other cationic lipids [1] Group 3 - The study successfully constructed a modular cmRNA-LNP platform integrated with mi3 nanoparticles, overcoming the technical limitations of traditional subunit vaccines and achieving synergistic enhancement of humoral and cellular immunity [2] - This technology not only provides a new generation solution for the development of swine viral vaccines but also has the potential to be expanded to other animal disease vaccines [2]

8月1日申联生物(688098)收盘价8.48元，收盘涨停，全天换手率7.26%，振幅20.11%，成交额2.41亿元。 科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 资金流向方面，该股今日全天主力资金净流入5780.88万元。（数据宝） 申联生物8月1日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 华鑫证券有限责任公司上海云锦路证券营业部 | 2975.55 | | 甬兴证券有限公司宁波和源路证券营业部 | 1800.98 | | 国泰海通证券股份有限公司上海浦东新区福山路证券营业部 | 1045.16 | | 华泰证券股份有限公司江西分公司 | 827.08 | | 开源证券股份有限公司西安西大街证券营业部 | 758.71 | | 卖出营业部名称 | 卖出金额(万元) | | 机构专用 | 1666.89 | | 中信建投证券股份有限公司广西分公司 | 805.60 | | 国泰海通证券股份有限公司临沂沂蒙路证券营业部 | 424.00 | | 上海证券有限责任公司宝山友谊路证券营业部 | 351.97 | | 机构专用 | 301.87 | （ ...

Group 1 - The animal vaccine sector experienced a rise of 2.22%, leading the concept sectors in terms of growth, with 13 stocks increasing in value, including Shenyuan Biological which hit the daily limit, and Yongshun Biological, Kexing Pharmaceutical, and Jinhai Biological showing notable gains of 6.32%, 4.08%, and 3.32% respectively [1][2] - The main inflow of funds into the animal vaccine sector amounted to a net inflow of 51 million yuan, with Kexing Pharmaceutical receiving the highest net inflow of 72.79 million yuan, followed by Shenyuan Biological, Kanghua Biological, and Xianfeng Holdings with net inflows of 57.81 million yuan, 46.82 million yuan, and 7.03 million yuan respectively [2][3] - The net inflow ratios for Shenyuan Biological, Xianfeng Holdings, and Kexing Pharmaceutical were 23.96%, 11.45%, and 9.02% respectively, indicating strong investor interest in these stocks [3] Group 2 - The animal vaccine sector's performance was contrasted by declines in other sectors, such as the China Shipbuilding System which fell by 2.54%, and the military equipment restructuring concept which decreased by 1.90% [2] - The trading volume and turnover rates for leading stocks in the animal vaccine sector were significant, with Shenyuan Biological showing a turnover rate of 7.26% and Kexing Pharmaceutical at 7.15% [3][4] - Several stocks within the animal vaccine sector experienced negative net inflows, including Guoyao Modern, Biological Shares, and Zhongmu Shares, which saw declines of 0.70%, 0.58%, and 0.52% respectively [1][4]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 26.53 | -4.91% | 2.94万 | 7940.17万 | | | 600201 | 生物股份 | 8.52 | -0.58% | 24.78万 | | 2.12亿 | | 600195 | 中牧股份 | 7.60 | -0.52% | 11.37万 | 8684.99万 | | | 688526 | 科前生物 | 16.83 | 0.12% | 2.68万 | 4545.18万 | | | 603566 | 普莱柯 | 14.87 | 0.41% | 4.54万 | 6795.60万 | | | 871970 | 大禹生物 | 10.30 | 0.49% | 3.25万 | 3391.36万 | | | 002141 | 贤丰控股 | 3.64 | 0.55% | 16.94万 | 6146.30万 | | | 300119 | 瑞普生物 | 21.31 | 0.85% | 8.70万 ...